Cargando…

Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters

The development of novel optimized vaccines against coronavirus disease 2019 (COVID-19) that are capable of controlling the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and the appearance of different variants of concern (VoC) is needed to fully prevent the transmission of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdelnabi, Rana, Pérez, Patricia, Astorgano, David, Albericio, Guillermo, Kerstens, Winnie, Thibaut, Hendrik Jan, Coelmont, Lotte, Weynand, Birgit, Labiod, Nuria, Delgado, Rafael, Montenegro, Dolores, Puentes, Eugenia, Rodríguez, Esteban, Neyts, Johan, Dallmeier, Kai, Esteban, Mariano, García-Arriaza, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619667/ https://www.ncbi.nlm.nih.gov/pubmed/37920464 http://dx.doi.org/10.3389/fimmu.2023.1163159

Ejemplares similares

MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters
por: Boudewijns, Robbert, et al.
Publicado: (2022)

Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection
por: Pérez, Patricia, et al.
Publicado: (2022)

Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters
por: Sharma, Sapna, et al.
Publicado: (2022)

The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters
por: Abdelnabi, Rana, et al.
Publicado: (2022)

Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model
por: Abdelnabi, Rana, et al.
Publicado: (2021)

Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters
por: Abdelnabi, Rana, et al.
Publicado: (2022)

The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model
por: Abdelnabi, Rana, et al.
Publicado: (2021)

Ivermectin Does Not Protect against SARS-CoV-2 Infection in the Syrian Hamster Model
por: Foo, Caroline S., et al.
Publicado: (2022)

Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters
por: Abdelnabi, Rana, et al.
Publicado: (2021)

A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection
por: Pérez, Patricia, et al.
Publicado: (2022)

Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatment
por: Abdelnabi, Rana, et al.
Publicado: (2023)

Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases
por: Perdiguero, Beatriz, et al.
Publicado: (2023)

HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect
por: Foo, Caroline S., et al.
Publicado: (2022)

Immunogenic Profiling in Mice of a HIV/AIDS Vaccine Candidate (MVA-B) Expressing Four HIV-1 Antigens and Potentiation by Specific Gene Deletions
por: García-Arriaza, Juan, et al.
Publicado: (2010)

Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of Care
por: Delang, Leen, et al.
Publicado: (2010)

Intranasal administration of convalescent plasma protects against SARS-CoV-2 infection in hamsters
por: Wouters, Elise, et al.
Publicado: (2023)

Immune responses triggered by HIV/AIDS vaccine candidates, derived from MVA-B, with deletions in several immune regulatory genes
por: García-Arriaza, J, et al.
Publicado: (2012)

Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B
por: Pérez, Patricia, et al.
Publicado: (2020)

Optimized Hepatitis C Virus (HCV) E2 Glycoproteins and their Immunogenicity in Combination with MVA-HCV
por: Marín, María Q., et al.
Publicado: (2020)

Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways
por: García-Arriaza, Juan, et al.
Publicado: (2013)

Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2
por: Mooij, Petra, et al.
Publicado: (2022)

Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression
por: Q. Marín, María, et al.
Publicado: (2018)

The combined vaccination protocol of DNA/MVA expressing Zika virus structural proteins as efficient inducer of T and B cell immune responses
por: Pérez, Patricia, et al.
Publicado: (2021)

Small-molecule inhibitors of TBK1 serve as an adjuvant for a plasmid-launched live-attenuated yellow fever vaccine
por: Sharma, Sapna, et al.
Publicado: (2020)

A Candidate HIV/AIDS Vaccine (MVA-B) Lacking Vaccinia Virus Gene C6L Enhances Memory HIV-1-Specific T-Cell Responses
por: García-Arriaza, Juan, et al.
Publicado: (2011)

DNA-launched RNA replicon vaccines induce potent anti-Ebolavirus immune responses that can be further improved by a recombinant MVA boost
por: Öhlund, Pontus, et al.
Publicado: (2018)

Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models
por: Ma, Ji, et al.
Publicado: (2022)

Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice
por: Lázaro-Frías, Adrián, et al.
Publicado: (2022)

An MVA Vector Expressing HIV-1 Envelope under the Control of a Potent Vaccinia Virus Promoter as a Promising Strategy in HIV/AIDS Vaccine Design
por: Pérez, Patricia, et al.
Publicado: (2019)

Tauopathy Analysis in P301S Mouse Model of Alzheimer Disease Immunized with DNA and MVA Poxvirus-Based Vaccines Expressing Human Full-Length 4R2N or 3RC Tau Proteins
por: García-Arriaza, Juan, et al.
Publicado: (2020)

Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model
por: Imbrechts, Maya, et al.
Publicado: (2022)

The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
por: Abdelnabi, Rana, et al.
Publicado: (2022)

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity
por: Kaptein, Suzanne J. F., et al.
Publicado: (2020)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
por: García-Arriaza, Juan, et al.
Publicado: (2021)

A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART
por: Gómez, Carmen Elena, et al.
Publicado: (2015)

A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice
por: Kum, Dieudonné Buh, et al.
Publicado: (2020)

Dendritic Cells Exposed to MVA-Based HIV-1 Vaccine Induce Highly Functional HIV-1-Specific CD8(+) T Cell Responses in HIV-1-Infected Individuals
por: Climent, Núria, et al.
Publicado: (2011)

Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization
por: C. Guardo, Alberto, et al.
Publicado: (2017)

STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters
por: Boudewijns, Robbert, et al.
Publicado: (2020)

Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B
por: Rosás-Umbert, Miriam, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kufpmd1s97ta3g2g76h74l6rbc